AstraZeneca’s SATURN “Moon Shot” Pitting Crestor Against Lipitor Misses The Mark
Executive Summary
Top-line results from AstraZeneca’s SATURN trial in atherosclerosis seem unlikely to prevent erosion of Crestor’s (rosuvastatin) market share once generic versions of Pfizer’s Lipitor (atorvastatin) enter the market in November.
You may also be interested in...
Amid The Lipitor Scuffle, What’s Next For Crestor?
Expiration of the Lipitor patent puts tremendous pressure on AstraZeneca’s bestselling statin, Crestor, which accounts for 20% of total revenues. AstraZeneca insists the drug’s value proposition will enable it to withstand the onslaught, but analysts expect a gradual chipping away at market share.
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.
Battle Of The Blockbusters: Lipitor Vs. Crestor In Atherosclerosis Progression Study Begins
1,300-patient, two-year Cleveland Clinic trial measures rate of regression of coronary disease.